Loading
Latest filing published 29 Nov 2022 for NRX Pharmaceuticals, Inc., €3,014. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Patrick John Flynn, listed as board member, appears in our data through filings on NRX Pharmaceuticals, Inc. shares, published by SEC (Form 4). In total, 2 filings cover trades dated from 24 May 2021 to 28 November 2022.
Purchases make up the whole of the open-market record (1 purchase, €3,014). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 1 share grant. Since January 2022: 1 purchase and no sales on the market.
The latest filing, published on 29 November 2022, reports an open-market purchase of €3,014 in NRX Pharmaceuticals, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations